Delving into the Latest Updates on BI-1060469 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

CRTH2

Action

antagonists

Mechanism

CRTH2 antagonists(Prostaglandin D2 receptor 2 antagonists)

Therapeutic Areas

Immune System DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

Asthma

Originator Organization

Boehringer Ingelheim GmbH

Active Organization-

Inactive Organization

Boehringer Ingelheim GmbH

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF) Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose) in Healthy Female Subjects (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Study at Two Different Dose Strengths)

The primary objective is to investigate the relative bioavailability of two newly developed tablet formulations of BI 1060469 vs BI 1060469 TF1 formulation. The secondary objective is the comparison of several pharmacokinetic parameters between the treatments.

Start Date01 May 2015

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT02202512

/ CompletedPhase 1

Effect of Repeated Oral Doses of BI 1060469, BI 1021958 and Active Controls, Cimetidine and Naproxen, on Measured GFR Via Renal Clearance of Iohexol in Healthy Male Subjects (a Phase I Study; Single-blind, Randomized, Placebo-controlled Within BI Groups and Open-label for the Active Controls)

Main objective is to investigate the measured glomerular filtration rate (mGFR) as assessed by iohexol clearance in healthy male normovolemic subjects after oral administration of single and repeated doses of BI 1060469, and BI 1021958.
The secondary objective of this trial is to investigate the glomerular filtration rate (GFR) as assessed by 24 hours creatinine clearance in healthy male normovolemic subjects after oral administration of single and repeated doses of BI 1060469, and BI 1021958.

Start Date01 Sep 2014

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT02225626

/ CompletedPhase 1

Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects

Effect of food on the pharmacokinetics of BI 1060469 (formulation tablet) in healthy male subjects as well as to investigate pharmacokinetics, safety and tolerability

Start Date01 Sep 2014

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with BI-1060469

Login to view more data

100 Translational Medicine associated with BI-1060469

Login to view more data

100 Patents (Medical) associated with BI-1060469

Login to view more data

100 Deals associated with BI-1060469

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Phase 1	Germany	Boehringer Ingelheim GmbH	01 May 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ERS2016	Phase 1	CRTH2	-	BI 1060469	(xjebkishau) = mild: headache, oropharyngeal pain, upper abdominal pain, rash, dry eyes dnemocoqtk (hassgckyoi )	Positive	01 Sep 2016
				Placebo